https://pubmed.ncbi.nlm.nih.gov/35724798/
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had...
Befotertinib of 75 to 100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC harboring T790M mutation...
https://pubmed.ncbi.nlm.nih.gov/39089004/
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC:...
Befotertinib demonstrated a more profound OS benefit compared to other 3rd-generation EGFR TKI, despite that cross trial data comparison should be interpreted...
https://pubmed.ncbi.nlm.nih.gov/38638860/
Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations...
The discovery of epidermal growth factor receptor (EGFR) somatic mutations and the availability of tyrosine kinase inhibitors (TKIs) as targeted therapies have...
small cell lung cancer